ARC 101
Alternative Names: ARC-101Latest Information Update: 31 Jan 2025
Price :
$50 *
At a glance
- Originator Third Arc Bio
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 06 Nov 2024 Preclinical trials in Solid tumours in USA (Parenteral) prior to November 2024
- 04 Nov 2024 Third Arc Bio plans a phase I trial for Solid tumours (Late-stage disease) (Parenteral) in February 2024 (NCT06672185)